Crexont®: A Newly Approved Parkinson’s Medication

New Carbidopa/Levodopa Formulation Approved for Reducing OFF Time Amneal Pharmaceuticals, Inc. announced today that their new medication IPX203, now known as...see more Crexont®, was approved by the Food and Drug Administration. Crexont is a novel oral formulation of carbidopa-levodopa extended-release capsules. Similar to Amneal’s Rytary, it contains both immediate-release and extended-release elements in the capsule and is designed […]

Read More

AMERICAN PARKINSON DISEASE ASSOCIATION CELEBRATES THE NATIONAL PLAN TO END PARKINSON’S ACT BECOMING LAW

APDA remains steadfast in its mission to support those impacted by Parkinson’s disease as new law provides hope for...see more accelerated progress toward a cure NEW YORK, NY, JULY 3, 2024 – The American Parkinson Disease Association (APDA) is celebrating the President’s signing of the National Plan to End Parkinson’s Act yesterday, marking the enactment of […]

Read More

Historic News for the PD Community

The National Plan to End Parkinson’s Act Has Been Signed into Law Today we celebratethe President’s signing of the...see more National Plan to End Parkinson’s Act, marking the enactment of the first-ever federal legislation dedicated to curing and preventing Parkinson’s disease (PD) and ensuring quality care for those impacted by this chronic and progressive neurologic disease. […]

Read More

AMERICAN PARKINSON DISEASE ASSOCIATION ANNOUNCES NEW RESOURCES AVAILABLE IN MANDARIN & SIMPLIFIED CHINESE

APDA is Committed to Reaching & Supporting More People with Parkinson’s Disease NEW YORK, NY, JUNE 24, 2024 –...see more The mission of the American Parkinson Disease Association (APDA) is to provide the support, education, and research to help everyone impacted by Parkinson’s disease (PD) live life to the fullest. To promote health equality and access […]

Read More

Understanding levodopa-induced dyskinesias: APDA-funded research published 

Congratulations to our 2020 APDA Research Grant Awardee Dr. Karen Jaunarajs for her work on understanding levodopa induced dyskinesias....see more Her study was recently published in Journal of Neuroscience. Dr. Jaunarajs works closely with Dr. David Standaert, Chairman of APDA’s Scientific Advisory Board, and the Chairman of University of Alabama at Birmingham’s Department of Neurology, which […]

Read More